Sensitization to minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade

American Journal of Transplantation

Volumn 10, Issue 7, 2010, Pages 1569-1579

  Xu, H ^a   Huang, Y ^a   Hussain, L R ^a   Zhu, Z ^a   Bozulic, L D ^a   Ding, C ^a   Yan, J ^a   Ildstad, S T ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Bone marrow transplantation; humoral immune response; minor histocompatibility antigen; sensitization

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; GAMMA INTERFERON; H 57 597; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; GRAFT RECIPIENT; GRAFT REJECTION; HUMORAL IMMUNITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD40; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CHILD; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; ISOANTIGENS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, INBRED AKR; MICE, INBRED STRAINS; MINOR HISTOCOMPATIBILITY ANTIGENS; SKIN TRANSPLANTATION; SPLEEN; TRANSPLANTATION CHIMERA;

EID: 77954060808     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03148.x     Document Type: Article

References (45)

1. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007 138 : 291 304.
2. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: A critical review of the literature and transfusion guidelines. Transfus Med Rev 2007 21 : 118 133.
3. Vermylen C. Hematopoietic stem cell transplantation in sickle cell disease. Blood Rev 2003 17 : 163 166.
4. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005 353 : 1135 1146.
5. Iannone R, Casella JF, Fuchs EJ et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003 9 : 519 528.
6. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005 35 : 171 177.
7. Taylor PA, Lees CJ, Wilson JM et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002 100 : 3400 3407.
8. Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996 157 : 2820 2829.
9. Xu H, Chilton PM, Huang Y, Schanie CL, Ildstad ST. Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism. J Immunol 2004 172 : 1463 1471.
10. Colson YL, Schuchert MJ, Ildstad ST. The abrogation of allosensitization following the induction of mixed allogeneic chimerism. J Immunol 2000 165 : 637 644.
11. Xu H, Chilton PM, Tanner MK et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006 108 : 3611 3619.
12. Xu H, Yan J, Huang Y et al. Co-stimulatory blockade of CD154:CD40 in combination with T cell lymphodepletion results in prevention of allogeneic sensitization. Blood 2008 111 : 3266 3275. PMCID: PMC2265462.
13. Taylor PA, Ehrhardt MJ, Roforth MM et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007 109 : 1307 1315.
14. Spierings E, Goulmy E. Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest 2005 115 : 3397 3400. (Pubitemid 43121825)
15. Simpson E, Scott D, James E et al. Minor H antigens: Genes and peptides. Eur J Immunogenet 2001 28 : 505 513.
16. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996 334 : 281 285.
17. Tseng LH, Lin MT, Hansen JA et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999 94 : 2911 2914.
18. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 1983 302 : 159 161.
19. Zimring JC, Hair GA, Deshpande SS, Horan JT. Immunization to minor histocompatibility antigens on transfused RBCs through crosspriming into recipient MHC class I pathways. Blood 2006 107 : 187 189.
20. Billingham RE. Free skin grafting in mammals.
21. Mobley JL, Rigby SM, Dailey MO. Regulation of adhesion molecule expression by CD8 T cells in vivo. II. Expression of L-selectin (CD62L) by memory cytolytic T cells responding to minor histocompatibility antigens. J Immunol 1994 153 : 5443 5452.
22. Kemp JD, Thorson JA, Gomez F, Smith KM, Cowdery JS, Ballas ZK. Inhibition of lymphocyte activation with anti-transferrin receptor Mabs: A comparison of three reagents and further studies of their range of effects and mechanism of action. Cell Immunol 1989 122 : 218 230.
23. Bishop GA, Hostager BS. Molecular mechanisms of CD40 signaling. Arch Immunol Ther Exp (Warsz) 2001 49 : 129 137.
24. Little CC, Tyzzer EE. Further experimental studies on the inheritance of susceptibilityy to a transplantable tumor, carcinoma (J.WA.) of Japanese waltzing mouse. J Med Res 1916 33 : 393 453.
25. Gorer PA. The genetic and antigenic basis for tumor transplantation. J Pathol Bacteriol 1937 44 : 691 697.
26. Dausset J, Nenna A. [Presence of leuko-agglutinin in the serum of a case of chronic agranulocytosis.]. C R Seances Soc Biol Fil 1952 146 : 1539 1541.
27. Payne R, Rolfs MR. Fetomaternal leukocyte incompatibility. J Clin Invest 1958 37 : 1756 1763.
28. van Rood JJ, Eernisse JG, Van LA. Leucocyte antibodies in sera from pregnant women. Nature 1958 181 : 1735 1736.
29. Bailey DW. Sizing up the set of H genes in mice. In : Roopenian D, Simpson E, eds. Minor histocompatibility antigens: From the Laboratory to the Clinic.
30. Spierings E, Hendriks M, Absi L et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet 2007 3 : e103.
31. Storb R. B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients. Blood 2009 113 : 1205.
32. Mendoza LM, Paz P, Zuberi A, Christianson G, Roopenian D, Shastri N. Minors held by majors: The H13 minor histocompatibility locus defined as a peptide/MHC class I complex. Immunity 1997 7 : 461 472.
33. Malarkannan S, Horng T, Eden P et al. Differences that matter: Major cytotoxic T cell-stimulating minor histocompatibility antigens. Immunity 2000 13 : 333 344.
34. Robertson NJ, Chai JG, Millrain M et al. Natural regulation of immunity to minor histocompatibility antigens. J Immunol 2007 178 : 3558 3565.
35. Roopenian DC. What are minor histocompatibility loci? A new look at an old question. Immunol Today 1992 13 : 7 10.
36. Blondeau B. The sensitized patient. Immunol Report 2005 2 : 17 20.
37. Fowler DH. B-ware of allosensitized graft rejection. Blood 2007 109 : 851 852.
38. Guan H, Nagarkatti PS, Nagarkatti M. Role of CD44 in the differentiation of Th1 and Th2 cells: CD44-deficiency enhances the development of Th2 effectors in response to sheep RBC and chicken ovalbumin. J Immunol 2009 183 : 172 180.
39. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003 4 : 33 45.
40. Naor D, Nedvetzki S, Walmsley M et al. CD44 involvement in autoimmune inflammations: The lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann NY Acad Sci 2007 1110 : 233 247.
41. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: A paradigm for cytokine receptor signaling. Ann Rev Immunol 1997 15 : 563 591.
42. Young HA. Regulation of interferon-gamma gene expression. J Interferon Cytokine Res 1996 16 : 563 568.
43. Nejat S, Zaki A, Hirsch GM, Lee TD. CD8(+) T cells mediate aortic allograft vasculopathy under conditions of calcineurin immunosuppression: Role of IFN-gamma and CTL mediators. Transpl Immunol 2008 19 : 103 111.
44. Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002 22 : 317 349.
45. Taylor PA, Ehrhardt MJ, Roforth MM et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007 109 : 1307 1315.